Business context and reporting period
Senseonics Holdings, Inc. is a medical technology company focused on its implantable Eversense continuous glucose monitoring (CGM) systems. This Form 10-K reports the fiscal year ended December 31, 2021; the filing text does not provide separate fourth-quarter results. The company sells primarily through Ascensia, which assumed U.S. commercial responsibilities for the 90-day product during the second quarter of 2021. The FDA approved the six-month Eversense E3 system in February 2022, after year-end.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $13.7 million | $4.9 million |
| Gross profit (loss) | $(0.8) million | $(17.4) million |
| Gross margin | (5.9)% | (350.9)% |
| Operating loss | $(57.2) million | $(79.1) million |
| Net loss | $(302.5) million | $(175.2) million |
| Net loss per share | $(0.72) | $(0.77) |
| Net cash used in operating activities | $(56.1) million | $(67.4) million |
Revenue increased $8.7 million, primarily reflecting Ascensia’s distribution orders. Ascensia accounted for 90% of 2021 revenue. The gross-loss improvement was attributed mainly to lower inventory impairment and use of inventory previously written off. Sales and marketing expense fell to $7.6 million from $20.6 million as commercial responsibilities shifted to Ascensia; research and development expense rose to $27.2 million from $20.4 million.
Net loss included $174.2 million of expense from changes in fair value of embedded derivatives and $53.2 million of option fair-value expense. These valuation changes are substantially non-cash and materially affected reported earnings. Total other expense was $245.3 million, versus $96.0 million in 2020.
At year-end, cash and cash equivalents were $33.5 million and marketable securities were $148.3 million, for combined liquidity of $181.8 million. Current assets were $144.4 million and current liabilities $18.4 million. Outstanding debt principal totaled $104.8 million, including $2.9 million due in 2022, $15.7 million in 2023, $35.0 million in 2024 and $51.2 million in 2025. Total liabilities were $384.5 million; stockholders’ deficit was $185.5 million. Financing activities provided $220.1 million in cash, including substantial equity issuance. Common shares outstanding increased from 265.6 million at year-end 2020 to 447.3 million at year-end 2021.
Material changes, outlook and risks
- Management said existing cash and expected operating cash flows should fund anticipated operating needs through 2023, based on current plans. It may seek additional capital to support changed plans, strategic initiatives or financial flexibility.
- Ascensia is the exclusive commercialization partner for the company’s 90-day and six-month products, subject to territorial exceptions. The agreement includes revenue sharing and minimum revenue and sales-and-marketing requirements. Future revenue is expected to depend substantially on Ascensia’s performance.
- Management expected Ascensia to launch Eversense E3 in the U.S. in the second quarter of 2022. Success depends on user growth, provider awareness and inserter availability, favorable reimbursement, and transition of payor coverage from the 90-day to six-month product. European E3 rollout remained subject to regulatory certification and launch uncertainty.
- The company plans to seek FDA authorization for a clinical trial of a 365-day sensor in the first half of 2022 and, if authorized, target enrollment in the second half of 2022. These are plans, not guaranteed milestones.
- Key risks include persistent losses and no established path to profitability; reliance on one product and Ascensia; reimbursement and adoption uncertainty; competition from larger CGM companies; COVID-19 effects on clinic access and insertions; and dependence on contract manufacturers and a limited supplier base.
- Two legal and regulatory matters warrant attention: a False Claims Act and Texas Medicaid fraud case pursued by a relator, with the company’s motion to dismiss pending; and an Italian privacy-authority proceeding concerning an unintended disclosure of user email addresses. The authority had found GDPR violations and the company’s response was pending, with a formal decision expected in the second quarter of 2022.
- The auditor issued an unqualified opinion on the financial statements and internal controls. The critical audit matter was valuation of derivatives and options, including significant unobservable assumptions. The filing also reports no material litigation contingency accrued at year-end.
Important facts for investors to verify
- Whether Eversense E3 launched on schedule and whether user, provider, inserter, and payor coverage growth supports commercial adoption.
- Whether cash use and operating plans remain consistent with management’s stated runway through 2023, including any financing needs or debt-covenant constraints.
- How the large derivative and option fair-value liabilities, debt maturities, and potential share dilution evolve; reported 2021 net loss was heavily affected by non-cash valuation changes.
- Developments and potential financial or operational consequences from the Italian GDPR proceeding and the relator-led False Claims Act case.
- Whether reported revenue growth converts into sustainable product demand and improved gross margins, given Ascensia’s 90% share of 2021 revenue.